Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes

It is postulated that localized tissue oxidative stress is a key component in the development of diabetic nephropathy. There remains controversy, however, as to whether this is an early link between hyperglycemia and renal disease or develops as a consequence of other primary pathogenic mechanisms. In the kidney, a number of pathways that generate reactive oxygen species (ROS) such as glycolysis, specific defects in the polyol pathway, uncoupling of nitric oxide synthase, xanthine oxidase, NAD(P)H oxidase, and advanced glycation have been identified as potentially major contributors to the pathogenesis of diabetic kidney disease. In addition, a unifying hypothesis has been proposed whereby mitochondrial production of ROS in response to chronic hyperglycemia may be the key initiator for each of these pathogenic pathways. This postulate emphasizes the importance of mitochondrial dysfunction in the progression and development of diabetes complications including nephropathy. A mystery remains, however, as to why antioxidants per se have demonstrated minimal renoprotection in humans despite positive preclinical research findings. It is likely that the utility of current study approaches, such as vitamin use, may not be the ideal antioxidant strategy in human diabetic nephropathy. There is now an increasing body of data to suggest that strategies involving a more targeted antioxidant approach, using agents that penetrate specific cellular compartments, may be the elusive additive therapy required to further optimize renoprotection in diabetes.

[1]  M. Cooper,et al.  Inhibition of NADPH Oxidase Prevents Advanced Glycation End Product–Mediated Damage in Diabetic Nephropathy Through a Protein Kinase C-α–Dependent Pathway , 2008, Diabetes.

[2]  Anja Voigt,et al.  Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. , 2007, Cell metabolism.

[3]  E. Bertini,et al.  COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. , 2007, Journal of the American Society of Nephrology : JASN.

[4]  F. DeRubertis,et al.  Acceleration of diabetic renal injury in the superoxide dismutase knockout mouse: effects of tempol. , 2007, Metabolism: clinical and experimental.

[5]  J. Ingelfinger,et al.  Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. , 2007, Kidney international.

[6]  D. Tripathi,et al.  Intermittent fasting prevents the progression of type I diabetic nephropathy in rats and changes the expression of Sir2 and p53 , 2007, FEBS letters.

[7]  J. Smeitink,et al.  Superoxide production is inversely related to complex I activity in inherited complex I deficiency. , 2007, Biochimica et biophysica acta.

[8]  M. Cooper,et al.  Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? , 2007, Endocrinology.

[9]  Maristela L Onozato,et al.  Double-Edged Action of SOD Mimetic in Diabetic Nephropathy , 2007, Journal of cardiovascular pharmacology.

[10]  C. Forsblom,et al.  A Functional Polymorphism in the Manganese Superoxide Dismutase Gene and Diabetic Nephropathy , 2007, Diabetes.

[11]  J. Gross,et al.  The Catalase –262C/T Promoter Polymorphism and Diabetic Complications in Caucasians with Type 2 Diabetes , 2007, Disease markers.

[12]  C. Wilcox,et al.  NADPH oxidases in the kidney. , 2006, Antioxidants & redox signaling.

[13]  H. Kamijo,et al.  Chronic Inhibition of Nitric Oxide Production Aggravates Diabetic Nephropathy in Otsuka Long-Evans Tokushima Fatty Rats , 2006, Nephron Physiology.

[14]  A. Hipkiss Does Chronic Glycolysis Accelerate Aging? Could This Explain How Dietary Restriction Works? , 2006, Annals of the New York Academy of Sciences.

[15]  Min Zhu,et al.  Calorie restriction mimetics: an emerging research field , 2006, Aging cell.

[16]  M. Nangaku,et al.  A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice. , 2006, Diabetes.

[17]  B. Isermann,et al.  Functional polymorphisms of UCP2 and UCP3 are associated with a reduced prevalence of diabetic neuropathy in patients with type 1 diabetes. , 2006, Diabetes care.

[18]  M. Nangaku,et al.  In a type 2 diabetic nephropathy rat model, the improvement of obesity by a low calorie diet reduces oxidative/carbonyl stress and prevents diabetic nephropathy. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  H. Abboud,et al.  Nox4 NAD(P)H Oxidase Mediates Hypertrophy and Fibronectin Expression in the Diabetic Kidney* , 2005, Journal of Biological Chemistry.

[20]  J. Tavaré,et al.  The human glomerular podocyte is a novel target for insulin action. , 2005, Diabetes.

[21]  R. Atkins,et al.  Kidney expression of glutathione peroxidase-1 is not protective against streptozotocin-induced diabetic nephropathy. , 2005, American journal of physiology. Renal physiology.

[22]  V. Monnier,et al.  Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. , 2005, American journal of physiology. Renal physiology.

[23]  J. Arenas,et al.  Renal pathology in children with mitochondrial diseases , 2005, Pediatric Nephrology.

[24]  N. Komai,et al.  NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. , 2005, American journal of physiology. Renal physiology.

[25]  Maristela L Onozato,et al.  Effects of NADPH oxidase inhibitor in diabetic nephropathy. , 2005, Kidney international.

[26]  Y. Sekino,et al.  Osmotic Diuretics Induce Adenosine A1 Receptor Expression and Protect Renal Proximal Tubular Epithelial Cells against Cisplatin-mediated Apoptosis* , 2004, Journal of Biological Chemistry.

[27]  S. Prabhakar Role of nitric oxide in diabetic nephropathy. , 2004, Seminars in nephrology.

[28]  F. Mohr,et al.  Effect of a β2-Adrenoceptor Stimulation on Hyperglycemia-Induced Endothelial Dysfunction , 2004, Journal of Pharmacology and Experimental Therapeutics.

[29]  M. Brand,et al.  Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. , 2004, Diabetes.

[30]  Simon Melov,et al.  Endogenous mitochondrial oxidative stress: neurodegeneration, proteomic analysis, specific respiratory chain defects, and efficacious antioxidant therapy in superoxide dismutase 2 null mice , 2003, Journal of neurochemistry.

[31]  F. Mohr,et al.  Effect of a beta 2-adrenoceptor stimulation on hyperglycemia-induced endothelial dysfunction. , 2004, The Journal of pharmacology and experimental therapeutics.

[32]  L. Denner,et al.  Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. , 2004, Diabetes.

[33]  L. Scorrano,et al.  Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction. , 2003, The Journal of clinical investigation.

[34]  E. Araki,et al.  Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy. , 2003, Diabetes.

[35]  S. Matsumoto,et al.  Confirmation of Superoxide Generation via Xanthine Oxidase in Streptozotocin-induced Diabetic Mice , 2003, Free radical research.

[36]  V. D’Agati,et al.  RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. , 2003, The American journal of pathology.

[37]  A. Munnich,et al.  Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia , 2002, Heart.

[38]  Maristela L Onozato,et al.  Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. , 2002, Kidney international.

[39]  Zhiquan Zhang,et al.  High Glucose Inhibits Glucose-6-phosphate Dehydrogenase via cAMP in Aortic Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[40]  M. Cooper,et al.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study , 2000, BMJ : British Medical Journal.

[41]  G. Damante,et al.  Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. , 2000, Diabetes.

[42]  Y. Kaneda,et al.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.

[43]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[44]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[45]  Paul J Thornalley,et al.  Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. , 1999, The Biochemical journal.

[46]  S. Kim,et al.  Role of Nitric Oxide in the Pathogenesis of Diabetic Nephropathy in Streptozotocin-Induced Diabetic Rats , 1999, The Korean journal of internal medicine.

[47]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[48]  Uk-Prospective-Diabetes-Study-Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[49]  M. Cooper,et al.  Pathogenesis, prevention, and treatment of diabetic nephropathy , 1998, The Lancet.

[50]  Paul J Thornalley Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. , 1998, Chemico-biological interactions.

[51]  Paul J Thornalley,et al.  Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. , 1998, The Journal of clinical investigation.

[52]  A. Munnich,et al.  Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxia , 1997, Nature Genetics.

[53]  G. Jerums,et al.  Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats , 1997, Diabetologia.

[54]  M. Kobayashi,et al.  Recombinant insulin-like growth factor I normalizes expression of renal glucose transporters in diabetic rats. , 1997, The American journal of physiology.

[55]  G. King,et al.  Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. , 1997, Journal of the American Society of Nephrology : JASN.

[56]  K. Federlin,et al.  A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[57]  P. Pandolfi,et al.  Targeted disruption of the housekeeping gene encoding glucose 6‐phosphate dehydrogenase (G6PD): G6PD is dispensable for pentose synthesis but essential for defense against oxidative stress. , 1995, The EMBO journal.

[58]  S. Freytag,et al.  Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. , 1995, The Journal of clinical investigation.

[59]  A. Schmidt,et al.  Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. , 1995, The Journal of clinical investigation.

[60]  M. Cooper,et al.  Role of Endothelium-Derived Nitric Oxide in the Pathogenesis of the Renal Hemodynamic Changes of Experimental Diabetes , 1994, Diabetes.

[61]  R W Alexander,et al.  Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. , 1994, Circulation research.

[62]  J. Baynes,et al.  Glycation, Glycoxidation, and Cross-Linking of Collagen by Glucose: Kinetics, Mechanisms, and Inhibition of Late Stages of the Maillard Reaction , 1994, Diabetes.

[63]  K. O. Elliston,et al.  Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. , 1992, The Journal of biological chemistry.

[64]  J. Turrens,et al.  Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. , 1980, The Biochemical journal.